$SILO
Silo Pharma, Inc. Stock $silo

$silo Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000121390023039078 Filed on May 12, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q4
Revenue	$18.03K	$64.39K	$18.03K
YoY Change	-0.03%	257.12%	0.0%
Cost Of Revenue	$1.459K	$1.460K	$1.460K
YoY Change	0.0%	0.0%	0.0%
Gross Profit	$16.57K	$16.57K	$16.57K
YoY Change	0.0%	-0.02%	0.0%
Gross Profit Margin	91.91%	25.73%	91.9%
Selling, General & Admin	$239.1K	$64.97K	$1.039M
YoY Change	822.52%	-82.61%	115.07%
% of Gross Profit	1443.32%	392.16%	6269.4%
Research & Development	$130.7K	$202.9K	$634.7K
YoY Change	23.7%	19.16%	33.35%
% of Gross Profit	789.08%	1224.88%	3830.3%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.132M	$820.1K	$1.674M
YoY Change	121.5%	50.79%	74.51%
Operating Profit	-$1.115M	-$803.5K	-$1.657M
YoY Change	125.58%	52.39%	75.82%
Interest Expense	$1.863K	$1.655K	-$6.160K
YoY Change	-101.14%	-101.03%	-94.63%
% of Operating Profit
Other Income/Expense, Net	$102.0K	-$102.9K	$280.00
YoY Change	-162.17%	-220.04%
Pretax Income	-$1.013M	-$906.4K	-$1.663M
YoY Change	53.85%	50.34%	57.31%
Income Tax		$906.4K	$0.00
% Of Pretax Income
Net Earnings	-$1.013M	-$906.4K	-$1.663M
YoY Change	53.85%	50.05%	52.74%
Net Earnings / Revenue	-5619.7%	-1407.71%	-9222.57%
Basic Earnings Per Share	-$0.32	-$0.29
Diluted Earnings Per Share	-$0.32	-$0.29	-$0.52
COMMON SHARES
Basic Shares Outstanding	3.159M shares	3.159M shares	3.139M shares
Diluted Shares Outstanding	3.154M shares	3.159M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.988M	$10.68M	$11.37M
YoY Change	12.89%	13.51%	10.85%
Cash & Equivalents	$158.8K	$4.666M	$11.37M
Short-Term Investments	$9.829M	$6.017M	$3.120K
Other Short-Term Assets	$121.3K	$204.4K	$135.9K
YoY Change	21.4%	-1.02%	-6.49%
Inventory
Prepaid Expenses			$21.17K
Receivables
Other Receivables			$60.00K
Total Short-Term Assets	$10.18M	$10.95M	$11.57M
YoY Change	13.75%	13.89%	11.24%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$3.118K
YoY Change			-99.26%
Other Assets	$67.90K	$69.36K	$70.82K
YoY Change	6.78%	97.05%	15.7%
Total Long-Term Assets	$67.90K	$69.36K	$70.82K
YoY Change	-30.24%	-28.93%	-19.4%
TOTAL ASSETS
Total Short-Term Assets	$10.18M	$10.95M	$11.57M
Total Long-Term Assets	$67.90K	$69.36K	$70.82K
Total Assets	$10.25M	$11.02M	$11.64M
YoY Change	13.28%	13.46%	10.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.048M	$660.3K	$364.2K
YoY Change	572.2%	323.77%	-12.85%
Accrued Expenses			$20.13K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00
YoY Change
Total Short-Term Liabilities	$1.120M	$732.4K	$436.3K
YoY Change	316.67%	150.17%	-10.96%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$829.7K	$847.8K	$865.8K
YoY Change	-7.99%	-7.84%	-7.69%
Total Long-Term Liabilities	$829.7K	$847.8K	$865.8K
YoY Change	-8.0%	-7.84%	-7.69%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.120M	$732.4K	$436.3K
Total Long-Term Liabilities	$829.7K	$847.8K	$865.8K
Total Liabilities	$1.950M	$1.580M	$1.302M
YoY Change	66.56%	30.31%	-8.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$9.090M	-$8.078M	-$7.171M
YoY Change	100.89%		119.8%
Common Stock	$311.00	$316.00	$316.00
YoY Change	-96.87%		-96.8%
Preferred Stock			$17.51M
YoY Change
Treasury Stock (at cost)	$16.20K
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.296M	$9.444M	$10.34M
YoY Change
Total Liabilities & Shareholders Equity	$10.25M	$11.02M	$11.64M
YoY Change	13.28%	13.46%	10.99%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	-$1.013M	-$906.4K	-$1.663M
YoY Change	53.85%	50.05%	52.74%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$550.0K	-$692.7K	-$886.0K
YoY Change	37.46%	-12.23%	14.49%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$3.826M	-$6.008M	$0.00
YoY Change	-5835.65%	-30141.7%	-100.0%
Cash From Investing Activities	-$3.826M	-$6.008M	$0.00
YoY Change	-5835.65%	-30141.7%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-131.0K		0.000
YoY Change
NET CHANGE
Cash From Operating Activities	-550.0K	-$692.7K	-886.0K
Cash From Investing Activities	-3.826M	-$6.008M	0.000
Cash From Financing Activities	-131.0K		0.000
Net Change In Cash	-4.507M	-$6.701M	-886.0K
YoY Change	1251.92%		108.76%
FREE CASH FLOW
Cash From Operating Activities	-$550.0K	-$692.7K	-$886.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	us-gaap	Other Income OtherIncome		usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets		usd
CY2023Q1	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation		usd
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-41512
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-3046338
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	560 Sylvan Avenue
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 3160
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Englewood Cliffs
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07632
CY2023Q1	dei	City Area Code CityAreaCode	(718)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	400,9031
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	SILO
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3158797	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4666007	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11367034	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	6013578	usd
CY2023Q1	silo	Equity Investments At Cost EquityInvestmentsAtCost	3508	usd
CY2022Q4	silo	Equity Investments At Cost EquityInvestmentsAtCost	3118	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	204348	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	135894	usd
CY2023Q1	us-gaap	Interest Receivable Noncurrent InterestReceivableNoncurrent	7193	usd
CY2022Q4	us-gaap	Interest Receivable Noncurrent InterestReceivableNoncurrent	6010	usd
CY2023Q1	silo	Note Receivable Noncurrent Including Interest Receivable NoteReceivableNoncurrentIncludingInterestReceivable	67193	usd
CY2022Q4	silo	Note Receivable Noncurrent Including Interest Receivable NoteReceivableNoncurrentIncludingInterestReceivable	66010	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	10954634	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	11572056	usd
CY2023Q1	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	69361	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	70821	usd
CY2023Q1	us-gaap	Assets Assets	11023995	usd
CY2022Q4	us-gaap	Assets Assets	11642877	usd
CY2023Q1	us-gaap	Loans Payable Current LoansPayableCurrent	660279	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	364216	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	72102	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	72102	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	732381	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	436318	usd
CY2023Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	847757	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	865782	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	847757	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	865782	usd
CY2023Q1	us-gaap	Liabilities Liabilities	1580138	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1302100	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3158797	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3158797	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3158797	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3158797	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	316	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	316	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17515826	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17511589	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5239	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8077524	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7171128	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	9443857	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10340777	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11023995	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11642877	usd
CY2023Q1	silo	License Fees LicenseFees	18026	usd
CY2022Q1	silo	License Fees LicenseFees	18026	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	1460	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	1460	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	16566	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	16566	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	162257	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	127181	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	365270	usd
CY2022Q1	us-gaap	Professional Fees ProfessionalFees	196248	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	202913	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	170279	usd
CY2023Q1	us-gaap	General Insurance Expense GeneralInsuranceExpense	24645	usd
CY2022Q1	us-gaap	General Insurance Expense GeneralInsuranceExpense	33292	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-20000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	64966	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	36825	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	820051	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	543825	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-803485	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-527259	usd
CY2022Q1	silo	Equity Shares Earned For Services EquitySharesEarnedForServices	-85733	usd
CY2023Q1	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	64388	usd
CY2022Q1	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	415	usd
CY2022Q1	us-gaap	Other Income OtherIncome	85733	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	1655	usd
CY2023Q1	silo	Penalty Expense PenaltyExpense	166034	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	390	usd
CY2022Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-161798	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-102911	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-75650	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	906396	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	602909	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-906396	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-602909	usd
CY2022Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-1163	usd
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1163	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-906396	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-604072	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-906396	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-604072	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	5239	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-901157	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-604072	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.29
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.31
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3158797	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1972739	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10340777	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4237	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	5239	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-906396	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	9443857	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9062266	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	45009	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-604072	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	8503203	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-906396	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-604072	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-20000	usd
CY2023Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	4237	usd
CY2022Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	45009	usd
CY2023Q1	silo	Amortization Of Prepaid Stockbased Expense AmortizationOfPrepaidStockbasedExpense	33775	usd
CY2023Q1	silo	Net Unrealized Lossgain Loss On Equity Investments NetUnrealizedLossgainLossOnEquityInvestments	390	usd
CY2022Q1	silo	Net Unrealized Lossgain Loss On Equity Investments NetUnrealizedLossgainLossOnEquityInvestments	-161798	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	100769	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	69667	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	906396	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	692688	usd
CY2023Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1183	usd
CY2022Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1184	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	296063	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-262130	usd
CY2022Q1	silo	Increase Decrease In Assets Of Discontinued Operation IncreaseDecreaseInAssetsOfDiscontinuedOperation	64839	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-18025	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-18025	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-692688	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-789165	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	6008339	usd
CY2022Q1	silo	Collection On Note Receivable CollectionOnNoteReceivable	20000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6008339	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	20000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-6701027	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-769165	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11367034	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9837001	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4666007	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9067836	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	167689	usd
CY2022Q1	silo	Common Stock Issued For Future Services CommonStockIssuedForFutureServices	76	usd
CY2021Q3	silo	Purchase Agreement PurchaseAgreement	60000	usd
CY2021Q3	us-gaap	Debt Instrument Repurchase Amount DebtInstrumentRepurchaseAmount	60000	usd
CY2021Q3	us-gaap	Investment Interest Rate InvestmentInterestRate	0.08	pure
CY2021Q3	us-gaap	Investment Maturity Date InvestmentMaturityDate	2023-10-01
CY2023Q1	us-gaap	Retained Earnings Unappropriated RetainedEarningsUnappropriated	8077524	usd
CY2023Q1	silo	Working Capital WorkingCapital	10222253	usd
CY2022Q4	silo	Less Notes Receivable Net Current Portion LessNotesReceivableNetCurrentPortion	67193	usd
CY2021Q4	silo	Less Notes Receivable Net Current Portion LessNotesReceivableNetCurrentPortion	66160	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future events. Accordingly, the actual results could differ significantly from estimates. Significant estimates during the three months ended March 31, 2023 and 2022 include the collectability of notes receivable, the percentage of completion of research and development projects, valuation of equity investments, valuation allowances for deferred tax assets, the fair value of warrants issued with debt and for services, and the fair value of shares and stock options issued for services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
CY2023Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q1	silo	Cash Spic Insured Amount CashSPICInsuredAmount	250000	usd
CY2023Q1	us-gaap	Fdic Indemnification Asset Cash Payments Received FDICIndemnificationAssetCashPaymentsReceived	4163000	usd
CY2022	us-gaap	Fdic Indemnification Asset Cash Payments Received FDICIndemnificationAssetCashPaymentsReceived	10868000	usd
CY2023Q1	us-gaap	Payments For Fees PaymentsForFees	166034	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	5239	usd
CY2023Q1	silo	Promissory Note PromissoryNote	0.08	pure
CY2023Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	204348	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	135894	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	69361	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	70821	usd
CY2023Q1	us-gaap	Derivative Maturity Dates DerivativeMaturityDates	2023-10-01
CY2023Q1	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	60000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	202913	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	170279	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	433429	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	375929	shares
CY2023Q1	silo	Shares Of Common Equity SharesOfCommonEquity	1559	shares
CY2022Q4	silo	Shares Of Common Equity SharesOfCommonEquity	1559	shares
CY2023Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	54.99
CY2021Q3	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	60000	usd
CY2021Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	60000	usd
CY2021Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.08	pure
CY2021Q3	us-gaap	Investment Maturity Date InvestmentMaturityDate	2023-10-01
CY2023Q1	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	60000	usd
CY2023Q1	us-gaap	Interest Receivable InterestReceivable	7193	usd
CY2023Q1	us-gaap	Financing Receivables Before Allowance For Credit Loss Average Amount Outstanding FinancingReceivablesBeforeAllowanceForCreditLossAverageAmountOutstanding	67193	usd
CY2022Q4	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	60000	usd
CY2022Q4	us-gaap	Interest Receivable InterestReceivable	6010	usd
CY2022	us-gaap	Financing Receivables Before Allowance For Credit Loss Average Amount Outstanding FinancingReceivablesBeforeAllowanceForCreditLossAverageAmountOutstanding	66010	usd
CY2022Q1	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	1079	usd
CY2022Q1	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	-1079	usd
CY2022Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	84	usd
CY2022Q1	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	-1163	usd
CY2022Q4	us-gaap	Notes Receivable Net NotesReceivableNet	60000	usd
CY2021Q4	us-gaap	Notes Receivable Net NotesReceivableNet	60000	usd
CY2022Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	7193	usd
CY2021Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	6160	usd
CY2022Q1	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	30000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	16000	shares
CY2023Q1	us-gaap	Interest Receivable InterestReceivable	7193	usd
CY2023Q1	us-gaap	Payments To Acquire Receivables PaymentsToAcquireReceivables	67193	usd
CY2022	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	60000	usd
CY2022Q4	us-gaap	Interest Receivable InterestReceivable	6010	usd
CY2022	us-gaap	Payments To Acquire Receivables PaymentsToAcquireReceivables	66010	usd
CY2023Q1	us-gaap	Excess Stock Shares Authorized ExcessStockSharesAuthorized	505000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q1	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	4280	shares
CY2021Q2	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	4049	shares
CY2022Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	227	shares
CY2022Q1	silo	Public Offering Shares PublicOfferingShares	1000000	shares
CY2021Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2026-12-26
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	pursuant to an Employment Agreement (see Note 8), an aggregate of 16,000 incentive stock options were issued under the 2020 Plan, to Dr. Kou, exercisable at $10.00 per share and expires on January 31, 2032. The stock options vest as follows: (i) 6,000 stock options upon issuance; (ii) 5,000 vests on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023.
CY2023Q1	us-gaap	Deferred Compensation Equity DeferredCompensationEquity	4237	usd
CY2022Q1	us-gaap	Deferred Compensation Equity DeferredCompensationEquity	45009	usd
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	152619	shares
CY2022Q4	us-gaap	Officers Compensation OfficersCompensation	350000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	100000	usd
CY2022Q3	us-gaap	Loans Payable LoansPayable	42000	usd
CY2022Q3	us-gaap	Officers Compensation OfficersCompensation	60000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10
CY2021Q2	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	625000	shares
CY2021Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.85
CY2022Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2032-01-31
CY2022Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	6000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5000	shares
CY2023Q1	us-gaap	Other Deferred Costs Net OtherDeferredCostsNet	4237	usd
CY2022Q1	us-gaap	Other Deferred Costs Net OtherDeferredCostsNet	9416	usd
CY2023Q1	us-gaap	Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense	9888	usd
CY2021Q1	silo	License Fee LicenseFee	10000	usd
CY2023Q2	us-gaap	Payments For Fees PaymentsForFees	1000	usd
CY2023Q1	silo	Commercial Sale Term CommercialSaleTerm	P10Y
CY2023Q1	silo	License Agreement Expire LicenseAgreementExpire	P15Y
CY2023Q1	silo	Sublicense Income Receivable Percentage SublicenseIncomeReceivablePercentage	0.15	pure
CY2023Q1	silo	Due To Related Partie Current DueToRelatedPartieCurrent	25000	usd
CY2022Q1	us-gaap	Fees Paid On Acceptances Resold FeesPaidOnAcceptancesResold	50000	usd
CY2021Q1	silo	License Fee LicenseFee	25000	usd
CY2022Q1	silo	License Fee LicenseFee	50000	usd
CY2022Q1	us-gaap	Long Term Debt Term LongTermDebtTerm	P15Y
CY2022	silo	License Fee LicenseFee	1250	usd
CY2023Q1	silo	Schedule Of Milestone Payments ScheduleOfMilestonePayments	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Milestone</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Payment</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">250,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Receipt of New Drug Application (“NDA”) (or foreign equivalent) approval for a Licensed Product</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Achievement of First Commercial Sale of Licensed Product</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q1	silo	Sales Of Licensed Products Percentage SalesOfLicensedProductsPercentage	0.05	pure
CY2023Q1	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	50000000	usd
CY2023Q1	silo	Schedule Of Umb Minimum Royalty Payments ScheduleOfUMBMinimumRoyaltyPayments	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Years</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Minimum<br/> Annual<br/> Royalty</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Prior to First Commercial Sale</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-90; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Year of First Commercial Sale</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-91; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">First calendar year following the First Commercial Sale</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Second calendar year following the First Commercial Sale</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">25,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Third calendar year following the First Commercial Sale</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023Q1	silo	License Fee LicenseFee	210	usd
CY2022Q1	silo	License Fee LicenseFee	210	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	838	usd
CY2023Q1	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	9986	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	838	usd
CY2022Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	10196	usd
CY2023Q1	silo	Nonrefundable Cash Payment NonrefundableCashPayment	500000	usd
CY2023Q1	silo	Net Sale Percentage NetSalePercentage	0.02	pure
CY2023Q1	silo	Licensor Share LicensorShare	500	shares
CY2023Q1	silo	Aggregate Of Converted Shares AggregateOfConvertedShares	625000	shares
CY2021Q1	silo	Aggregate Of Converted Shares AggregateOfConvertedShares	625000	shares
CY2021Q1	silo	Licensor Share LicensorShare	500	shares
CY2021Q1	silo	Nonrefundable Cash Payment NonrefundableCashPayment	500000	usd
CY2021Q1	silo	Revenue Term RevenueTerm	P15Y
CY2021	silo	Number Of Voting Shares NumberOfVotingShares	20000	shares
CY2021Q4	us-gaap	Excess Of Replacement Or Current Costs Over Stated Lifo Value ExcessOfReplacementOrCurrentCostsOverStatedLIFOValue	1000	usd
CY2021	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	0.8
CY2021Q2	silo	Trading Price TradingPrice	531250	usd
CY2021Q2	us-gaap	Equity Method Investments EquityMethodInvestments	531250	usd
CY2021Q2	us-gaap	Deferred Revenue DeferredRevenue	531250	usd
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue	1031250	usd
CY2023Q1	silo	Cash Received CashReceived	500000	usd
CY2023Q1	silo	Securities Received SecuritiesReceived	531250	usd
CY2023Q1	silo	Revenue Term RevenueTerm	P15Y
CY2023Q1	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	17187	usd
CY2022	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	17187	usd
CY2023Q1	silo	Deferred Revenue Current Portion DeferredRevenueCurrentPortion	68750	usd
CY2023Q1	silo	Deferred Revenue Longterm Portion Amounted DeferredRevenueLongtermPortionAmounted	807813	usd
CY2023Q1	silo	Consideration Fee Payable Percentage ConsiderationFeePayablePercentage	1.10	pure
CY2023Q1	silo	Upfront License Fees UpfrontLicenseFees	50000	usd
CY2023Q1	silo	First Commercial Sale FirstCommercialSale	P10Y
CY2023Q1	silo	Agreement Shall Expire AgreementShallExpire	P15Y
CY2021Q2	silo	Upfront License Fees UpfrontLicenseFees	50000	usd
CY2022	silo	Deferred Revenue Current Portion DeferredRevenueCurrentPortion	3352	usd
CY2022	silo	Deferred Revenue Longterm Portion Amounted DeferredRevenueLongtermPortionAmounted	40782	usd
CY2023Q1	us-gaap	Other Notes Payable OtherNotesPayable	81474	usd
CY2023Q1	silo	Sponsored Study Agreement SponsoredStudyAgreement	40737	usd
CY2021Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	40737	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	40737	usd
CY2021Q2	silo	Sublicense Amount Paid SublicenseAmountPaid	342850	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	60570	usd
CY2023Q1	silo	Schedule Of Shall Pay Umb ScheduleOfShallPayUMB	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Payment</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 6%; text-align: center">1</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">92,095</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 81%; text-align: left">Upon execution of the July 2021 Sponsored Research Agreement</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: center">2</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">92,095</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">Six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">3</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">92,095</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2021Q3	us-gaap	Short Term Lease Payments ShortTermLeasePayments	92095	usd
CY2022Q3	us-gaap	Short Term Lease Payments ShortTermLeasePayments	92095	usd
CY2022Q4	silo	Accounts Payable Related Partie Current AccountsPayableRelatedPartieCurrent	92095	usd
CY2023Q1	us-gaap	Cash Cash	430825	usd
CY2023Q1	us-gaap	Restructuring And Related Cost Expected Cost Remaining1 RestructuringAndRelatedCostExpectedCostRemaining1	143607	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	287215	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	143607	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.80	pure
CY2022Q4	us-gaap	Legal Fees LegalFees	41306	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	21172	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	33252	usd
CY2023Q1	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	8054	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets		usd
CY2023Q1	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold		usd
CY2023Q1	silo	Operating Leases Future Minimum Payment Due In Two Years OperatingLeasesFutureMinimumPaymentDueInTwoYears	831002	usd
CY2023Q1	silo	Operating Leases Future Minimum Payment Due OperatingLeasesFutureMinimumPaymentDue	831002	usd
CY2023Q1	silo	Payment Of University PaymentOfUniversity	5000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5000	usd
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5000	usd
CY2023Q1	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	1000000	shares
CY2023Q1	us-gaap	Excess Stock Shares Outstanding ExcessStockSharesOutstanding	1000000	shares
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Silo Pharma, Inc.
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2022Q1	us-gaap	Interest Expense InterestExpense		usd
CY2022Q1	silo	Penalty Expense PenaltyExpense		usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.31
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.00
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2022Q1	silo	Amortization Of Prepaid Stockbased Expense AmortizationOfPrepaidStockbasedExpense		usd
CY2023Q1	silo	Equity Shares Earned For Services EquitySharesEarnedForServices		usd
CY2023Q1	silo	Increase Decrease In Assets Of Discontinued Operation IncreaseDecreaseInAssetsOfDiscontinuedOperation		usd
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
CY2023Q1	silo	Collection On Note Receivable CollectionOnNoteReceivable		usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	silo	Common Stock Issued For Future Services CommonStockIssuedForFutureServices		usd
CY2023Q1	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets		usd
CY2023Q1	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss		usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet		usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets		usd
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001514183

Files In Submission

Name	View Source	Status
0001213900-23-039078-index-headers.html	Edgar Link	pending
0001213900-23-039078-index.html	Edgar Link	pending
0001213900-23-039078.txt	Edgar Link	pending
0001213900-23-039078-xbrl.zip	Edgar Link	pending
f10q0323ex31-1_silopharma.htm	Edgar Link	pending
f10q0323ex31-2_silopharma.htm	Edgar Link	pending
f10q0323ex32-1_silopharma.htm	Edgar Link	pending
f10q0323ex32-2_silopharma.htm	Edgar Link	pending
f10q0323_silopharma.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
f10q0323_silopharma_htm.xml	Edgar Link	completed
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
silo-20230331.xsd	Edgar Link	pending
silo-20230331_lab.xml	Edgar Link	unprocessable
silo-20230331_cal.xml	Edgar Link	unprocessable
silo-20230331_def.xml	Edgar Link	unprocessable
silo-20230331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SILO
Silo Pharma, Inc. Stock $silo

2023 Q2 Form 10-Q Financial Statement

#000121390023039078 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SILO Silo Pharma, Inc. Stock $silo

2023 Q2 Form 10-Q Financial Statement

#000121390023039078 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SILO
Silo Pharma, Inc. Stock $silo